Factors Associated With Fear of Cancer Recurrence in a Multiethnic Cohort of Patients With Breast Cancer

多民族乳腺癌患者队列中与癌症复发恐惧相关的因素

阅读:2

Abstract

BACKGROUND: Fear of cancer recurrence (FCR) is prevalent among patients with breast cancer, yet those at high risk are not well characterized. AIMS: This study aimed to identify the patient characteristics associated with FCR after diagnosis. METHODS: Between July and September 2023, participants in the Chicago Multiethnic Epidemiologic Breast Cancer Cohort completed the 9-item FCR-Short Form Inventory. A score of 22 or higher indicated clinically significant FCR (csFCR). Logistic and linear regression estimated associations between different risk factors and csFCR and FCR scores, respectively. Missing data were addressed using multiple imputation. RESULTS: Among 1390 stage I-III patients (mean age 63.1 years and 9.1 [mean] years since diagnosis), 262 (18.8%) reported csFCR. In adjusted models, csFCR was associated with having another cancer excluding non-melanoma skin (adjusted odds ratio [aOR], 2.64; 95% CI, 1.66-4.21), greater levels of stress (aOR, 2.40 per 1-SD increment; 95% CI, 1.98-2.91), having a prior recurrence (aOR, 2.26; 95% CI, 1.14-4.47), and having estrogen receptor-positive tumors (aOR, 1.60; 95% CI, 1.06-2.40). Older age at diagnosis (aOR, 0.64 per 10-year increment; 95% CI, 0.56-0.73) was associated with lower odds of csFCR. Similar associations were observed with continuous FCR scores, along with advanced stage at diagnosis associated with higher FCR scores (p-trend = 0.001). CONCLUSIONS: Nearly 1 in 5 breast cancer patients reported csFCR. Key risk factors included younger age at diagnosis, history of recurrence or other malignancies, greater levels of stress, and estrogen receptor-positive breast cancer, which can inform targeted interventions to support survivorship.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。